Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −51.5%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.13 0.44 −0.65%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 44.8×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Royalty Pharma PLC (RPRX) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
Income from financial royalty assets	2,261	95.08%
Other royalty income and revenues	117	4.92%
Gross margin		100.00%
Operating margin		65.58%
Pre-tax margin		55.68%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Income from financial royalty assets	2,261 95.08%	2,149 94.96%	2,198 93.34%	2,125 94.99%	2,065 90.20%	1,960 92.35%	1,649 90.88%	1,525 84.95%
Other royalty income and revenues	117 4.92%	114 5.04%	157 6.66%	112 5.01%	53 2.32%	19 0.90%	20 1.08%	136 7.57%
Intangible Royalty Assets	—	—	—	—	171 7.48%	143 6.76%	146 8.03%	134 7.47%
Revenue	2,378	2,264	2,355	2,237	2,289	2,122	1,814	1,795

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Announced transactions	Q1 FY2026	$1.3B	—	—
Capital deployment	Q3 FY2026	$362.0M	−$1.0B	+135.74%
Milestones and other contractual receipts	Q3 FY2026	$7.0M	$3.0M	+133.33%
Portfolio receipts	Q3 FY2026	$890.0M	$814.0M	+9.34%
Royalty receipts	Q3 FY2026	$883.0M	$811.0M	+8.88%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023
Announced transactions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Capital deployment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Milestones and other contractual receipts	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Portfolio receipts	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Royalty receipts	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.